Navigation Links
PharmAthene Reports First Quarter 2011 Financial and Operating Results
Date:5/11/2011

ANNAPOLIS, Md., May 11, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operating results for the first quarter ended March 31, 2011.

For the first quarter of 2011 PharmAthene recognized revenue of $6.3 million compared to $3.1 million in the same period of 2010.  Revenues for the most recent quarter consisted of contract funding from the U.S. government for the development of the Company's SparVax™ and Valortim® biodefense programs.  Revenue for the period ended March 31, 2011 increased $3.2 million, as compared to the same period in 2010, as a result of increased revenue for the SparVax™ program, which totaled $5.4 million for the three months ended March 31, 2011 compared to $2.1 million for the same period in 2010.  The increase in revenue for the Company's SparVax™ program is attributable to additional work completed during the quarter in relation to the Company's manufacturing platform for SparVax™ and the establishment of analytical and stability-indicating assays for characterization of the product.  The Company recognized $0.8 million of revenue for its Valortim® program for each of the three months ended March 31, 2011 and 2010, respectively.

Research and development expenses increased to $5.8 million for the period ended March 31, 2011 compared to $5.0 million in the same period of 2010.  These expenses resulted from research and development activities related to the Company's Valortim® and SparVax™ programs, and to a lesser extent, expenses related to the Protexia® bioscavenger program.  Research and development expenses increased for the period ended March 31, 2011 compared to the prior year period, primarily due to increased activity und
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
2. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
3. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
4. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
5. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
6. PharmAthene Announces Pricing of $15 Million Public Offering
7. PharmAthene Announces Proposed Common Stock Offering
8. PharmAthene Announces $3.9 Million Registered Direct Offering
9. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
10. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
11. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Utah , July 10, 2014 /PRNewswire-iReach/ ... annotation and interpretation, today announced an agreement ... (NGS) analytics for Lineagen,s NextStep Dx ... of neurodevelopmental and neurological disorders, currently offers ... microarray (CMA) testing service used by healthcare ...
(Date:7/10/2014)... July 10, 2014   Ceres, Inc . (Nasdaq: ... company, announced today financial results for the three months ... its business. Ceres reported that the company ... performance this growing season in Brazil, which concluded in ... company,s sorghum evaluation areas for part of the growing ...
(Date:7/10/2014)... in the fight against terrorism with the creation of ... with the use of light and special glass fibres. ... B: Chemical , the researchers describe a novel optical ... low as 6.3 ppm (parts per million). It requires ... "Traditionally explosives detection has involved looking for metals that ...
(Date:7/10/2014)... published today in the journal PNAS (Proceedings of ... time of day and sleep deprivation have a significant ... when looking at the best time of day to ... and for administering medicines effectively. , Researchers from the ... London, investigated the links between sleep deprivation, body clock ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2Time of day crucial to accurately test for diseases, new research finds 2
... by the National Nanotechnology Initiative (NNI) and the Oregon ... landscape of regional, state, and local (RSL) nanotechnology initiatives. ... visits on April 30 Where: Portland, Oregon ... Street, Portland, OR Who: Leaders of regional, ...
... PML Consortium, an association of pharmaceutical and biotechnology companies, ... from BioFortis to share and manage data relating to ... adverse event. Progressive multifocal leukoencephalopathy (PML) is ... immunocompromised patients. PML has been identified as a known ...
... about the disease and its overall occurrence and progression ... market. This is being exacerbated by the limited availability ... need for innovative and enhanced therapeutic and diagnostic tools ... treatment options. New analysis from Frost & ...
Cached Biology Technology:Registration now open: 2012 Regional, State, and Local Initiatives in Nanotechnology 2Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities 2European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 2European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 3
(Date:7/10/2014)... June 30, 2014  Aware, Inc. (NASDAQ: ... services, previously announced on June 26, 2014 that its ... of $1.75 per share, or approximately $40 million in ... 10, 2014 and a payment date of July 24, ... it had set an ex-dividend date for this special ...
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) has ... Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, ... to their offering http://photos.prnewswire.com/prnh/20130307/600769 ... Sensing Market to Grow Exponentially. Touch-less sensing applications ... companies were unable to leverage this technology due ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... new study published as the cover article for the April ... ) promises to give physicians new ways to reduce deadly ... cord. In the report, scientists from Columbia University, NY, detail ... cells, called astrocytes, use to handle invading viruses and to ...
... Novocell, Inc., a stem cell engineering company, today announced ... covering human definitive endoderm cells, an essential cell for ... developing for use as a cell therapy for diabetes, ... as lungs, intestine, liver, thymus and thyroid. ...
... CORVALLIS, Ore. Studies done with laboratory rats suggest that ... effect in lowering triglycerides, which along with cholesterol levels and ... cardiovascular disease. In the lab animals, supplements of lipoic ... effect were the same in humans which is not ...
Cached Biology News:West Nile virus studies show how star-shaped brain cells cope with infection 2New approach discovered to lowering triglycerides 2New approach discovered to lowering triglycerides 3
HybriWell™ hybridization sealing system, 22 mm x 22 mm chamber, 0.15 mm deep *set of 100*...
RABBIT ANTI ISOCITRATE DEHYDROGENASE...
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
Recombinant Equine IL-4, CF...
Biology Products: